DF Dent & Co. Inc. Has $14.49 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

DF Dent & Co. Inc. cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,418 shares of the life sciences company's stock after selling 13,397 shares during the period. DF Dent & Co. Inc. owned about 0.07% of Illumina worth $14,488,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ILMN. Golden State Wealth Management LLC acquired a new position in shares of Illumina in the 4th quarter valued at approximately $32,000. Versant Capital Management Inc grew its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina in the fourth quarter worth $45,000. Assetmark Inc. increased its position in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. bought a new stake in Illumina in the fourth quarter valued at $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN traded down $1.35 during mid-day trading on Tuesday, hitting $72.11. 1,224,530 shares of the stock were exchanged, compared to its average volume of 2,230,622. The company has a market cap of $11.42 billion, a P/E ratio of -9.41, a PEG ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a twelve month low of $69.55 and a twelve month high of $156.66. The stock's fifty day simple moving average is $95.52 and its two-hundred day simple moving average is $124.59. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on ILMN. Royal Bank of Canada cut their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday. Morgan Stanley reduced their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a report on Tuesday, February 11th. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday. Barclays restated an "underweight" rating on shares of Illumina in a research report on Tuesday, March 11th. Finally, TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and lowered their price objective for the company from $177.00 to $140.00 in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $139.85.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.